New molecules and treatment modulation in advanced prostatic cancer.
Mahler
C
C
Dept. Endocrinology, Oncologic Centre Antwerp, A.Z. Middelheim, Antwerp, Belgium.
Verhelst
J
J
Denis
L
L
D000726:Androgen Antagonists / Q000627:therapeutic use; D000813:Anilides / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D005485:Flutamide / Q000037:antagonists & inhibitors; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D009570:Nitriles; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012176:Retinoids / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D013498:Suramin / Q000627:therapeutic use; D014105:Tosyl Compounds
D000726:Androgen Antagonists; D000813:Anilides; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D007093:Imidazoles; D009570:Nitriles; D012176:Retinoids; D014105:Tosyl Compounds; D013004:Somatostatin; D013498:Suramin; D005485:Flutamide; C053541:bicalutamide; C061121:liarozole